Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4399Urinary Bladder Neoplasms 1078Carcinoma, Renal Cell 1041Kidney Neoplasms 567Breast Neoplasms 453Neoplasms 403Carcinoma, Transitional Cell 299Neoplasm Metastasis 250Lung Neoplasms 242Testicular Neoplasms 202Melanoma 195Colorectal Neoplasms 193Ovarian Neoplasms 163Carcinoma, Non-Small-Cell Lung 150Sarcoma 135Non-Muscle Invasive Bladder Neoplasms 135Pancreatic Neoplasms 124Colonic Neoplasms 121Head and Neck Neoplasms 116Uterine Cervical Neoplasms 115Wilms Tumor 108Recurrence 106Motor Activity 100Stomach Neoplasms 89Urologic Neoplasms 88Neuroblastoma 88Disease 85Multiple Myeloma 83Carcinoma, Hepatocellular 79Adenocarcinoma 79

Interventions

Panitumumab 1Gemcitabine 1Cystectomy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cone Dystrophy 3 × Genitourinary × Clear all
NCT01916109 2016-02-12

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
4 enrolled 6 charts
Genitourinary

Cone Dystrophy 3, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡